Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mesoblast Ltd (MESO)
NASDAQ:MESO
Holding MESO?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-$0.15Last Year’s EPS
-$0.38Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 20, 2024
|% Change Since: 35.21%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Neutral
The call presented several positive developments, including successful clinical trials, FDA designations, and financial improvements. However, challenges remain with revenue diversification and regulatory approvals. Overall, the sentiment is cautiously optimistic with significant achievements but pending challenges.Company Guidance
During the earnings call for Mesoblast, several key metrics and guidance points were highlighted. The company reported cash reserves of USD 77.6 million as of December 31, 2023, following a successful institutional placement and entitlement offer of AUD 60.3 million. The cash burn for operating activities was reduced by 25% in the last quarter compared to the same period in FY 2023, amounting to USD 12.3 million. For the six-month period ending December 2023, the cash burn decreased by 14% compared to the previous year, while the loss after tax was reduced by 21% to USD 32.5 million. Additionally, Mesoblast's revenue reached USD 3.4 million, primarily from royalties on sales of TEMCELL in Japan. The company also provided an update on their upcoming pivotal trials and regulatory engagements, aiming to extend their cash runway beyond 12 months through potential strategic partnerships.Successful Phase III Trials and FDA Designations
Completed pivotal Phase III trial for pediatric steroid-refractory acute graft versus host disease, achieving primary endpoint. FDA granted regenerative medicine advanced therapeutic (RMAT) designation for heart failure and inflammatory back pain treatments.
Intellectual Property and Manufacturing Advancements
Mesoblast holds over 1,100 patents across major jurisdictions. Achieved scalable manufacturing processes with innovations like 3D bioreactors, inspected and approved by FDA at Lonza facility.
Financial Improvements
Cash reserves at USD 77.6 million with a 25% reduction in cash burn for operating activities in the last quarter compared to the previous year. Loss after tax reduced by 21%.
Pediatric Rare Disease and Orphan Drug Designations
Revascor received rare pediatric disease and orphan drug designations from FDA for hypoplastic left heart syndrome, potentially eligible for a priority review voucher.
---
MESO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MESO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 20, 2024 | $10.82 | $10.33 | -4.53% |
| Aug 28, 2024 | $6.37 | $6.47 | +1.57% |
| May 29, 2024 | $8.52 | $8.02 | -5.87% |
| Feb 28, 2024 | $2.09 | $1.97 | -5.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mesoblast Ltd (MESO) report earnings?
Mesoblast Ltd (MESO) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Mesoblast Ltd (MESO) earnings time?
Mesoblast Ltd (MESO) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MESO EPS forecast?
MESO EPS forecast for the fiscal quarter 2025 (Q2) is -$0.15.
---